Bernd R. Seizinger - 30 Jun 2021 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role: Director
Signature: /s/ Scott M. Coiante, attorney-in-fact
Issuer symbol: APRE
Transactions as of: 30 Jun 2021
Net transactions value: $0
Form type: 4
Filing time: 01 Jul 2021, 19:00:56 UTC
Next filing: 19 May 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APRE	Common Stock	Award	$0	+4,610	+1.7%	$0.000000	268,580	30 Jun 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APRE	Stock Option (Right to Buy)	Award	$0	+22,750		$0.000000	22,750	30 Jun 2021	Common Stock	22,750	$4.88	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares represent restricted stock units which were granted on June 30, 2021, and which will vest and be settled in common stock on June 30, 2022, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
F2	The option vests in full on June 30, 2022, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.